ThP tiaditinn-Tl catPgori ?:ation nf innovation as t^ithpr "inrrpnipntal " or "radical" is incomplete and fundanient al ly inisl eadi ng ."Generational" innovation - innovation ...
We examine the interface between for‐profit and publicly funded research in pharmaceuticals. Firms access upstream basic research through investments in absorptive capacity in t...
This paper begins to reconcile competing perspectives on the origins of competitive advantage by examining the adoption of 'science-driven' drug discovery, a performance-enhanci...
h-index: Number of publications with at least h citations each.